A new mouse model of experimental melanoma for vaccine and lymphokine therapy.

摘要: The annual incidence of malignant melanoma is estimated at 10-12 per 100,000 inhabitants in countries central Europe and the United States, alarmingly there has been a dramatic upward trend that estimate. B16 murine rapidly growing metastatic tumor spontaneous origin, as are human melanomas. Melanoma cells produce specific antigens which uniquely different from normal cellular antigens, expression such cornerstone for preparation anti-melanoma vaccines. One major problem evaluating effectiveness vaccination other biologic therapies variability experimental models. A new model was developed our laboratory imitates clinical stages melanoma: stage I, primary (local) growth bone marrow invasion; II, regional lymph node involvement; III, metastasis to distant organs, lungs. This used successfully screening vaccines constructed laboratory. Immunization with formalinized (of extracellular intact cells, or B700 antigen) irradiated cells) partially inhibit growth, reduce nodes lungs, significantly increase mean survival time. These anti-tumor effects were improved when polyvalent monovalent combined IL-2 therapy. We also compared immunogenic activity made transfected genes encoding GM-CSF, on bearing mice without therapy using corresponding lymphokines. In sum, comparison antibody production, tumors, number surviving mice, time, percent lung metastases, showed best course immunotherapy involves secrete coupled GM-CSF